Elvia Cowan - Feb 29, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, FINANCE
Signature
/s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Feb 29, 2024
Transactions value $
-$603,133
Form type
4
Date filed
3/4/2024, 09:22 PM
Previous filing
Sep 6, 2023
Next filing
Jul 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +5.4K +69.61% $0.00 13.2K Feb 29, 2024 Direct F1, F2
transaction PCVX Common Stock Options Exercise $285K +11K +83.6% $25.92 24.2K Mar 1, 2024 Direct
transaction PCVX Common Stock Sale -$170K -2.32K -9.61% $73.08 21.8K Mar 1, 2024 Direct F3, F4
transaction PCVX Common Stock Sale -$328K -4.46K -20.4% $73.69 17.4K Mar 1, 2024 Direct F3, F5
transaction PCVX Common Stock Sale -$367K -4.9K -28.2% $74.90 12.5K Mar 1, 2024 Direct F3, F6
transaction PCVX Common Stock Tax liability -$23.2K -324 -2.6% $71.55 12.2K Mar 2, 2024 Direct F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +25K $0.00 25K Feb 29, 2024 Common Stock 25K $73.82 Direct F8
transaction PCVX Stock Option (right to buy) Options Exercise $0 -11K -7.86% $0.00 129K Mar 1, 2024 Common Stock 11K $25.92 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 Includes 457 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023.
F3 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.365. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.465. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. The shares were sold at prices ranging from $74.47 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F8 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F9 1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.